— Know what they know.
Not Investment Advice

MYCOF OTC

Noveris Health Sciences Inc.
1W: +0.0% 1M: +0.0% 3M: -63.5% YTD: +234.9% 1Y: +12066.7% 3Y: +350.6% 5Y: +96.8%
$0.73
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Strong Sell · Power 40 · $42.7M mcap · 55M float · 0.0051% daily turnover · Short 55% of daily vol

Balance Sheet Trends

Total Assets
$51K -76.2% ▼
5Y CAGR: -65.4%
Total Liabilities
$15M +23.5% ▲
5Y CAGR: +130.3%
Shareholders Equity
-$15M -25.2% ▼
Cash & Investments
$325 -99.1% ▼
5Y CAGR: -55.3%
Total Debt
$7M +26.8% ▲
5Y CAGR: +156.1%
Net Debt
$7M +27.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$2M$1M$11K$38K$325
Short-Term Investments$0$0$7M$0$0
Cash & ST Investments$2M$1M$7M$38K$325
Net Receivables$41K$205K$363K$155K$50K
Inventory$47K-$205K$0$0$0
Other Current Assets$0$205K$0$0$0
Total Current Assets$2M$5M$9M$212K$51K
Property, Plant & Equip.$515K$565K$10K$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$5M$0$0$0$0
Other Non-Current Assets$1M$2M$679K$0$0
Total Non-Current Assets$7M$2M$689K$0$0
Total Assets$10M$8M$7M$212K$51K
— Liabilities —
Accounts Payable$841K$661K$5M$7M$7M
Short-Term Debt$3M$0$85K$5M$7M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$1M$385K$0$0
Total Current Liabilities$6M$3M$6M$12M$15M
Long-Term Debt$0$4M$5M$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$167K$4M$5M$0$0
Total Liabilities$6M$7M$11M$12M$15M
— Equity —
Common Stock$85M$108M$116M$126M$126M
Retained Earnings-$94M-$125M-$136M-$155M-$158M
Accumulated OCI-$445K$176K$176K$286K$0
Total Stockholders Equity$4M$211K-$4M-$12M-$15M
Total Liabilities & Equity$10M$8M$7M$212K$51K
— Key Metrics —
Total Debt$3M$5M$5M$5M$7M
Net Debt$1M$3M$5M$5M$7M
Total Investments$5M$0$7M$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms